The 15-20% who need the right result, fast
HER2 overexpression occurs in approximately 15% to 20% of advanced gastric and gastroesophageal junction (GEJ) cancers. For this group, confirmed HER2 status isn't secondary. It determines whether trastuzumab-based therapy enters first-line treatment at all.
The real issue isn't the biology. It's the gap between biopsy and a reliable result that actually gets used. This gap - measured in days or weeks - involves pathology reporting, oncologist review, and team coordination. In busy clinics, each handoff creates a delay. These delays matter clinically.
Why gastric cancer HER2 testing is harder than it looks
Clinicians who know HER2 in breast cancer can't use the same approach for gastric tumors. Two biological differences make testing harder in gastric cancer.
First, HER2 staining in gastric cancer is often incomplete. Breast cancer uses full circumferential membrane staining for scoring. Gastric cancer needs a different system that counts basolateral and lateral-only membrane patterns. Using breast criteria on a gastric sample produces errors.
Second, HER2 differences within the same tumor are more common in gastric cancer than breast tissue. A HER2 testing guide in Modern Pathology explains that uneven HER2 spread can make different blocks from the same tumor show different scores. The number of blocks taken, biopsy location, and fixation methods all change the result.
These factors mean an IHC score of 2+ (unclear) should trigger FISH testing to confirm or rule out amplification. That step needs clear coordination between pathology and oncology. Without a system to track this, unclear cases can wait in report lines longer than needed.
What the ToGA trial showed - and why testing accuracy matters
The ToGA trial made clear why correct HER2 identification matters clinically. According to the Journal of Clinical Oncology, patients with HER2-positive gastric cancer who got trastuzumab plus chemotherapy lived a median of 13.8 months, versus 11.1 months for chemotherapy alone. In patients with higher HER2 (IHC 3+ or IHC 2+ with FISH confirmation), the difference grew to 16.8 months versus 11.8 months.
These numbers assume the patient's HER2 status was identified correctly. When testing gets delayed, misread, or doesn't reach the oncologist before treatment starts, the benefit disappears. This is a clinical coordination problem, not a lab problem.
Local versus central testing: where results don't match
Registry studies have compared HER2 results from local labs against central reference labs. The results consistently showed disagreement.
The AGMT GASTRIC-5 Registry compared local and central HER2 testing in patients with advanced gastric and GEJ cancer. Patients with centrally confirmed HER2-positive results who got trastuzumab-based first-line therapy lived a median of 17.7 months. Those with centrally confirmed HER2-positive results who didn't get trastuzumab lived 6.9 months. The difference shows what a correct result costs in months when it doesn't lead to the right treatment.
The VARIANZ study, a multi-center trial, found mismatched HER2 results in 12% of cases between local and central labs. The main problem was misreading IHC at the local level: labs counted staining in the cell fluid (cytoplasm) as membrane staining, and called focal strong staining in under 10% of tumor cells HER2-positive.
Both studies point to the same operational lesson. The quality of HER2 testing depends on structured pathology review and reliable communication between local and central labs. Clinics that manage this through email and phone calls are working against themselves.
Where the testing handoff breaks down
The typical HER2 workup in advanced gastric cancer: endoscopic biopsy, formalin fixation and paraffin embedding, IHC staining, pathologist scoring, report generation, result delivery to oncologist, and - if IHC is 2+ - reflex FISH order, additional wait, second report, and second oncologist review.
The reflex FISH step often gets delayed. It needs a separate lab request, a fluorescence microscope, and a reader trained in FISH. If the reflex order doesn't trigger automatically when the IHC 2+ result is filed, someone in the clinic has to notice and order it. In practices with dozens of active patients, that notice doesn't always happen right away.
Multidisciplinary team (MDT) meetings are where oncology, pathology, and gastroenterology decide on treatment. When HER2 results are still pending at the MDT, the team defers the treatment decision to the next meeting slot. In centers that meet every other week, that delay can push first-line planning back by weeks. The patient isn't harmed during this time, but the window for best treatment timing keeps narrowing.
If test status and pending orders show up in one place, things change. Before the MDT meeting, the oncologist can see which patients have complete HER2 testing and who's still waiting for FISH. The team can schedule accordingly instead of discovering it mid-meeting.
Coordinating confirmed results with treatment planning
When HER2 comes back positive, the oncology team needs to act without delay. That means connecting the result to the treatment protocol under discussion, flagging it for the prescribing doctor, and making it visible to the full team - not hidden in a PDF or unstructured document store where it takes manual work to find.
Extracting structured data from pathology reports helps here. When the HER2 IHC or FISH result shows up as a searchable field in the patient record instead of buried in a multi-page PDF, the oncologist reads it in seconds instead of minutes. This speed matters most between appointments when treatment decisions get made. Learn how structured extraction changes clinical workflows.
For practices using integrative medicine, the challenge goes further. The integrative doctor managing nutrition or functional medicine for the same patient needs to know the HER2 status too. It shapes how they understand the patient's total treatment plan. They need unified records, not separate systems with separate logins.
The problem of coordinating biomarker results across an MDT appears in other cancers too. NSCLC workups need EGFR, ALK, and PD-L1 results before treatment planning can finish - explained in detail in EGFR, ALK, and PD-L1 Testing in NSCLC Clinic Workflows.
What structured coordination requires operationally
Closing the HER2 diagnosis-to-treatment gap doesn't need a lab redesign. It needs better information flow between existing teams and systems. Here's what's needed:
- A test status tracker at the patient level showing which HER2 steps are done and which are pending - IHC ordered, IHC resulted, reflex FISH triggered, FISH resulted.
- Automatic flagging when an IHC 2+ result is filed, prompting the reflex FISH order without someone having to notice it manually.
- Connection between the confirmed pathology result and the treatment timeline, so the oncologist's plan view shows actual HER2 status instead of just a placeholder.
- Visibility for the full MDT, including integrative clinicians, without separate logins or manual forwarding of results.
These are workflow and data problems, not lab problems. They can be solved with the right system design. Structured result data from pathology reports can feed directly into the treatment coordination view. Learn more about Why oncology clinics need treatment timelines, not just calendars.
See it in your clinic's workflow
Book a 30-minute demo to see this in action with your patient data. We'll show how pending reflex tests surface before MDT meetings and how confirmed results connect to the treatment timeline. Book a demo.